<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Med</journal-id>
<journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id>
<journal-id journal-id-type="publisher-id">jcm</journal-id>
<journal-title-group>
<journal-title>Journal of Clinical Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2077-0383</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32492904</article-id>
<article-id pub-id-type="pmc">7355965</article-id>
<article-id pub-id-type="doi">10.3390/jcm9061669</article-id>
<article-id pub-id-type="publisher-id">jcm-09-01669</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Anti-Diabetic Drug Metformin Rescues Aberrant Mitochondrial Activity and Restrains Oxidative Stress in a Female Mouse Model of Rett Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9723-3780</contrib-id>
<name>
<surname>Zuliani</surname>
<given-names>Ilaria</given-names>
</name>
<xref ref-type="aff" rid="af1-jcm-09-01669">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Urbinati</surname>
<given-names>Chiara</given-names>
</name>
<xref ref-type="aff" rid="af2-jcm-09-01669">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Valenti</surname>
<given-names>Daniela</given-names>
</name>
<xref ref-type="aff" rid="af3-jcm-09-01669">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quattrini</surname>
<given-names>Maria Cristina</given-names>
</name>
<xref ref-type="aff" rid="af4-jcm-09-01669">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Medici</surname>
<given-names>Vanessa</given-names>
</name>
<xref ref-type="aff" rid="af2-jcm-09-01669">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cosentino</surname>
<given-names>Livia</given-names>
</name>
<xref ref-type="aff" rid="af2-jcm-09-01669">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6370-912X</contrib-id>
<name>
<surname>Pietraforte</surname>
<given-names>Donatella</given-names>
</name>
<xref ref-type="aff" rid="af4-jcm-09-01669">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2013-209X</contrib-id>
<name>
<surname>Di Domenico</surname>
<given-names>Fabio</given-names>
</name>
<xref ref-type="aff" rid="af1-jcm-09-01669">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perluigi</surname>
<given-names>Marzia</given-names>
</name>
<xref ref-type="aff" rid="af1-jcm-09-01669">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2438-6449</contrib-id>
<name>
<surname>Vacca</surname>
<given-names>Rosa Anna</given-names>
</name>
<xref ref-type="aff" rid="af3-jcm-09-01669">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Filippis</surname>
<given-names>Bianca</given-names>
</name>
<xref ref-type="aff" rid="af2-jcm-09-01669">2</xref>
<xref ref-type="corresp" rid="c1-jcm-09-01669">*</xref>
</contrib>
</contrib-group>
<aff id="af1-jcm-09-01669"><label>1</label>Department of Biochemical Sciences, Sapienza University of Rome, 00185 Rome, Italy; <email>ilaria.zuliani@uniroma1.it</email> (I.Z.); <email>fabio.didomenico@uniroma1.it</email> (F.D.D.); <email>marzia.perluigi@uniroma1.it</email> (M.P.)</aff>
<aff id="af2-jcm-09-01669"><label>2</label>Center for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, 00161 Rome, Italy; <email>chiara.urbinati@iss.it</email> (C.U.); <email>vanessamedici3@gmail.com</email> (V.M.); <email>livia.cosentino@iss.it</email> (L.C.)</aff>
<aff id="af3-jcm-09-01669"><label>3</label>Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Council of Research, 70126 Bari, Italy; <email>d.valenti@ibbe.cnr.it</email> (D.V.); <email>r.vacca@ibiom.cnr.it</email> (R.A.V.)</aff>
<aff id="af4-jcm-09-01669"><label>4</label>Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy; <email>mariacristina.quattrini@iss.it</email> (M.C.Q.); <email>donatella.pietraforte@iss.it</email> (D.P.)</aff>
<author-notes>
<corresp id="c1-jcm-09-01669"><label>*</label>Correspondence: <email>bianca.defilippis@iss.it</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>6</month>
<year>2020</year>
</pub-date>
<volume>9</volume>
<issue>6</issue>
<elocation-id>1669</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>4</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Metformin is the first-line therapy for diabetes, even in children, and a promising attractive candidate for drug repurposing. Mitochondria are emerging as crucial targets of metformin action both in the periphery and in the brain. The present study evaluated whether treatment with metformin may rescue brain mitochondrial alterations and contrast the increased oxidative stress in a validated mouse model of Rett syndrome (RTT), a rare neurologic disorder of monogenic origin characterized by severe behavioral and physiological symptoms. No cure for RTT is available. In fully symptomatic RTT mice (12 months old MeCP2-308 heterozygous female mice), systemic treatment with metformin (100 mg/kg ip for 10 days) normalized the reduced mitochondrial ATP production and ATP levels in the whole-brain, reduced brain oxidative damage, and rescued the increased production of reactive oxidizing species in blood. A 10-day long treatment with metformin also boosted pathways related to mitochondrial biogenesis and antioxidant defense in the brain of metformin-treated RTT mice. This treatment regimen did not improve general health status and motor dysfunction in RTT mice at an advanced stage of the disease. Present results provide evidence that systemic treatment with metformin may represent a novel, repurposable therapeutic strategy for RTT.</p>
</abstract>
<kwd-group>
<kwd>Rett syndrome</kwd>
<kwd>metformin</kwd>
<kwd>repurposing</kwd>
<kwd>PGC-1α</kwd>
<kwd>Nrf2</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-jcm-09-01669" sec-type="intro">
<title>1. Introduction</title>
<p>Metformin is the most widely prescribed treatment for hyperglycemia and type 2 diabetes, even in pediatric patients [<xref ref-type="bibr" rid="B1-jcm-09-01669">1</xref>,<xref ref-type="bibr" rid="B2-jcm-09-01669">2</xref>]. It belongs to the class of biguanides and acts as a blood glucose-lowering agent by decreasing hepatic gluconeogenesis and improving insulin sensitivity. While metformin has been used to treat diabetes for over 60 years, recent evidences open up the possibility that this clinically approved drug may be repurposed for several other conditions, such as cancer, cardiovascular disorders, neurodegenerative diseases [<xref ref-type="bibr" rid="B3-jcm-09-01669">3</xref>], and more recently, neurodevelopmental disorders characterized by intellectual disability [<xref ref-type="bibr" rid="B4-jcm-09-01669">4</xref>,<xref ref-type="bibr" rid="B5-jcm-09-01669">5</xref>]. Moreover, treatment with metformin was demonstrated to counteract the deleterious effects of aging and provide beneficial effects on mouse healthspan and lifespan [<xref ref-type="bibr" rid="B6-jcm-09-01669">6</xref>].</p>
<p>The mechanisms of action of metformin have not been completely clarified. Energy metabolism is a clear focal point of metformin action and emerging evidence suggests that its therapeutic potential may reside in the capacity to target mitochondrial dysfunction [<xref ref-type="bibr" rid="B1-jcm-09-01669">1</xref>]. Chronic treatment with metformin in fact improves mitochondrial function and increases antioxidant protection. Consistent with the capability of metformin to pass the blood-brain barrier, these treatment effects have been evidenced both in the periphery and in the brain [<xref ref-type="bibr" rid="B7-jcm-09-01669">7</xref>,<xref ref-type="bibr" rid="B8-jcm-09-01669">8</xref>,<xref ref-type="bibr" rid="B9-jcm-09-01669">9</xref>,<xref ref-type="bibr" rid="B10-jcm-09-01669">10</xref>]. The exact nature of the interaction between metformin and mitochondria is still poorly characterized [<xref ref-type="bibr" rid="B11-jcm-09-01669">11</xref>,<xref ref-type="bibr" rid="B12-jcm-09-01669">12</xref>]. Metformin induces a weak but specific inhibition of the mitochondrial respiratory-chain (MRC) complex I in tissues such as skeletal muscle and liver [<xref ref-type="bibr" rid="B13-jcm-09-01669">13</xref>]. Even though complex I is the most studied mitochondrial target of metformin, several signaling pathways relevant for mitochondrial functionality have been found to be impacted by the drug. An emerging target is the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a transcriptional coactivator that plays key roles in mitochondrial biogenesis [<xref ref-type="bibr" rid="B14-jcm-09-01669">14</xref>]. The beneficial effects of metformin on mitochondrial dysfunction in fibroblasts from Down syndrome (DS) patients were in fact found to be due to the activation of the PGC-1α downstream targets that regulate the transcription of mitochondria-related genes and the activation of the core machinery that governs the dynamic mitochondrial remodeling [<xref ref-type="bibr" rid="B5-jcm-09-01669">5</xref>]. Furthermore, metformin increases antioxidant protection through the activation of PGC-1α downstream targets [<xref ref-type="bibr" rid="B15-jcm-09-01669">15</xref>,<xref ref-type="bibr" rid="B16-jcm-09-01669">16</xref>]. Taken together, these results suggest that treatment with metformin may represent a promising therapeutic strategy to correct mitochondrial dysfunction, even in the brain.</p>
<p>Defective mitochondrial energy production machinery and the resulting increased levels of free radicals are emerging as relevant factors in the pathogenesis of Rett syndrome (RTT) [<xref ref-type="bibr" rid="B17-jcm-09-01669">17</xref>], a rare neurological disorder which affects mainly females with an incidence of 1:10,000 live births. After a normal development until 6–18 months of age, patients start showing a progressive loss of previously acquired cognitive, social, and motor skills as a consequence of an early neurological regression. RTT patients may live beyond 50–60 years of age. In the majority of cases (95%), RTT arises from de novo mutations in the X-linked methyl CpG-binding protein 2 (<italic>MECP2</italic>) gene. The encoded MeCP2 protein is expressed ubiquitously but mostly in the brain and it is involved in several processes such as transcriptional regulation, modulation of chromatin structure and RNA splicing [<xref ref-type="bibr" rid="B18-jcm-09-01669">18</xref>].</p>
<p>Mitochondrial alterations so far identified in the brain and in hind limb muscle in RTT mouse models include ultrastructural changes, MRC impairment, oxidative phosphorylation (OXPHOS) deficiency and increased reactive oxidizing species (ROS) production [<xref ref-type="bibr" rid="B19-jcm-09-01669">19</xref>,<xref ref-type="bibr" rid="B20-jcm-09-01669">20</xref>,<xref ref-type="bibr" rid="B21-jcm-09-01669">21</xref>,<xref ref-type="bibr" rid="B22-jcm-09-01669">22</xref>]. Consistent with data on lymphomonocytes of RTT patients [<xref ref-type="bibr" rid="B23-jcm-09-01669">23</xref>,<xref ref-type="bibr" rid="B24-jcm-09-01669">24</xref>], mitochondrial dysfunction in RTT mouse brain is accompanied by the downregulation of the protein content of MRC complexes subunits [<xref ref-type="bibr" rid="B20-jcm-09-01669">20</xref>] and by reduced energy status in two highly validated RTT mouse models [<xref ref-type="bibr" rid="B22-jcm-09-01669">22</xref>]. An impaired antioxidant defense system with high levels of lipid peroxidation and markers of oxidative stress has been also detected both in the blood of RTT patients [<xref ref-type="bibr" rid="B25-jcm-09-01669">25</xref>] and in the brain of MeCP2-null mice [<xref ref-type="bibr" rid="B26-jcm-09-01669">26</xref>,<xref ref-type="bibr" rid="B27-jcm-09-01669">27</xref>]. Furthermore, dyslipidaemia, fatty liver disease, insulin resistance and metabolic syndrome were also uncovered [<xref ref-type="bibr" rid="B27-jcm-09-01669">27</xref>,<xref ref-type="bibr" rid="B28-jcm-09-01669">28</xref>], confirming that metabolic alterations in RTT patients and mouse models extend beyond mitochondria. </p>
<p>All these evidences suggest that MeCP2 plays an important role in the regulation of systemic metabolism and <italic>MECP2</italic> mutations provide profound metabolic dysfunctions both at the peripheral and central levels [<xref ref-type="bibr" rid="B29-jcm-09-01669">29</xref>]. However, the underlying mechanisms have not been completely clarified and it is currently unclear whether metabolic alterations play a key role in the pathogenesis of RTT. Based on these evidences, the present study addressed whether metformin may rescue brain mitochondrial alterations and contrast the increased oxidative stress in a validated RTT mouse model bearing a MeCP2 truncating mutation (MeCP2-308 mice) [<xref ref-type="bibr" rid="B30-jcm-09-01669">30</xref>,<xref ref-type="bibr" rid="B31-jcm-09-01669">31</xref>]. We reasoned that, by improving brain mitochondrial dysfunction, metformin may rescue the neurological phenotype, thus representing an innovative and repurposable therapeutic strategy for RTT.</p>
</sec>
<sec id="sec2-jcm-09-01669">
<title>2. Experimental Section</title>
<sec id="sec2dot1-jcm-09-01669">
<title>2.1. Subjects</title>
<p>The experimental subjects were MeCP2-308 heterozygous female (RTT) mice (B6.129S-MeCP2tm1Hzo/J, stock number: 005439; backcrossed to C57BL/6J mice for at least 12 generations from the Jackson Laboratories (USA) and wild-type (WT) littermates. MeCP2-mutated heterozygous females were used as a disease-related model, as they recapitulate the genetic and hormonal milieu of RTT patients [<xref ref-type="bibr" rid="B32-jcm-09-01669">32</xref>,<xref ref-type="bibr" rid="B33-jcm-09-01669">33</xref>]. Mice were housed in groups of 2-3 in polycarbonate transparent cages (33 × 13 × 14 cm) with sawdust bedding and kept on a 12h light-dark schedule (lights off at 8:00 am). Temperature was maintained at 21 ± 1°C and relative humidity at 60 ± 10%. Animals were provided with tap water ad libitum and a complete pellet diet (Altromin, Germany). Mice were tested at 12 months of age, an age at which they are fully symptomatic [<xref ref-type="bibr" rid="B19-jcm-09-01669">19</xref>,<xref ref-type="bibr" rid="B34-jcm-09-01669">34</xref>]. All procedures were carried out in accordance with the European Communities Council Directive (10/63/EU) as well as the Italian law (26/2014; approval number by the Italian Ministry for Health: DGSAF 763/2019-PR).</p>
</sec>
<sec id="sec2dot2-jcm-09-01669">
<title>2.2. Genotyping</title>
<p>DNA was prepared from a small tail-tip biopsy taken at 21–25 days of age, as previously described [<xref ref-type="bibr" rid="B35-jcm-09-01669">35</xref>]. The <italic>MeCP2</italic> alleles were identified by PCR using two sets of primers. Primer set 1 (5′ primer: 5′-AAC GGG GTA GAA AGC CTG-3′ and 3′ primer: 5′- ATG CTC CAG ACT GCC TTG -3′) yields a product of 396 bp identifying the wild-type allele. Primer set 2 (5′ primer: same as for primer set 1 and 3′ primer: 5′- TGA TGG GGT CCT CAG AGC -3′) yields a product of 318 bp identifying the null allele. PCR products were electrophoresed through a 2% NuSieve 3:1 agarose gel (Cambrex Bio Science, Rockland, ME, USA) containing 0.5 μg/mL ethidium bromide and examined under UV light.</p>
</sec>
<sec id="sec2dot3-jcm-09-01669">
<title>2.3. Drug Treatment and Experimental Design</title>
<p>Metformin (met-1,1-Dimethylbiguanide) was supplied by Sigma-Aldrich (St Louis, MO, USA) and stored at +4 °C. Metformin was dissolved in saline (sal-0.9% NaCl) and the quantity to be injected daily was calculated according to mouse weight (volume of intraperitoneal injection (ip): 10 mL/kg). RTT mice and WT littermate controls were randomly assigned to receive metformin or sal in a balanced way, according to weight and general health status.</p>
<p>In order to evaluate whether systemic treatment with metformin could rescue brain metabolic alterations and the defective general health status of RTT mice when they present the full symptomatology, on 1-year-old WT and RTT mice, we applied the 10-day long treatment regimen that ameliorates core symptoms in a mouse model of Fragile X [<xref ref-type="bibr" rid="B4-jcm-09-01669">4</xref>], a disorder of genetic origin with several symptoms in common with RTT. Metformin was first administered at the dose of 200 mg/kg, according to the protocol described in [<xref ref-type="bibr" rid="B4-jcm-09-01669">4</xref>]. However, on the first day of the treatment, 5 out of the 8 mice that received metformin (3 WT and 2 RTT) showed convulsions about an hour after the injection, while one of the experimental subjects did not survive. This prompted us to halve the dose and treat an additional cohort of mice with 100 mg/kg of metformin or saline for 10 days. This new dose was chosen as many studies have already addressed its efficacy [<xref ref-type="bibr" rid="B36-jcm-09-01669">36</xref>,<xref ref-type="bibr" rid="B37-jcm-09-01669">37</xref>]. Furthermore, a dose response curve has been previously performed [<xref ref-type="bibr" rid="B4-jcm-09-01669">4</xref>] that confirms that the concentration levels of metformin that can be achieved with the 100 mg/kg dose are comparable to those obtained with the standard dose used in humans for the treatment of type-2 diabetes (~20 mg/kg), with both giving plasma concentrations in the 10–20 µM range [<xref ref-type="bibr" rid="B38-jcm-09-01669">38</xref>].</p>
<p>To assess metformin effects on RTT-related behavioral alterations, experimental mice underwent a test battery 24 hours after the last ip (11<sup>th</sup> day of the schedule), as previously reported [<xref ref-type="bibr" rid="B4-jcm-09-01669">4</xref>]. In particular, we assessed treatment effects on general health status and motor function (open field task and dowel test). At the end of behavioral testing, the experimental mice were sacrificed, and blood and brains were collected for the subsequent mitochondrial and molecular analysis.</p>
</sec>
<sec id="sec2dot4-jcm-09-01669">
<title>2.4. Behavioral Assessments</title>
<p>Behavioral testing took place during the dark phase of the light/dark cycle, between 9:00 and 12:00 am, and was carried out by experimenters blind to the mouse genotype and treatment. Mice were experimentally naïve. Mice for each condition were as follows: WT, sal = 8; WT, met = 7; RTT, sal = 8; RTT, met = 8.</p>
<sec id="sec2dot4dot1-jcm-09-01669">
<title>2.4.1. Open Field Test</title>
<p>The open field test was performed 24 hours after the last injection to assess locomotor activity, exploratory habits and response to novelty. The apparatus consisted of a black plastic box (40 × 40 cm) enclosed by high walls (35 cm), with brightly illuminated floor (about 13 lux). Each mouse was individually placed inside the arena with its head facing one of the walls and allowed to freely explore the environment during a 10-min session as previously described [<xref ref-type="bibr" rid="B34-jcm-09-01669">34</xref>]. The floor of the apparatus was cleaned with 70% ethanol before each testing session. The total distance moved in the arena was automatically detected with specific behavioral tracking software (ANY-maze software Version 4.82, Ugo Basile SRL Gemonio, Italy).</p>
</sec>
<sec id="sec2dot4dot2-jcm-09-01669">
<title>2.4.2. Dowel Test</title>
<p>To evaluate the effects of metformin on motor coordination and balance, the dowel test was performed 5 minutes after the open field test as in [<xref ref-type="bibr" rid="B39-jcm-09-01669">39</xref>]. The hardwood round dowel used was 9 mm in diameter and 35 cm long. The dowel was mounted horizontally 50 cm above a 5 cm deep bedding of sawdust. At the beginning of the test, each mouse was placed in the middle of the dowel so that the length of its body was parallel to it. Latency to fall from the dowel was recorded (30 s cut-off). Each mouse repeated the test twice, with an intertrial interval of at least 15 min. If mice were able to walk across and off the dowel, they received the maximum score of 30 s.</p>
</sec>
<sec id="sec2dot4dot3-jcm-09-01669">
<title>2.4.3. General Health Evaluation</title>
<p>The general health of the experimental subjects was qualitatively evaluated by a trained observer, blind to the genotype and treatment of mice as previously described [<xref ref-type="bibr" rid="B40-jcm-09-01669">40</xref>], with little modification. The observation of mice was performed on a laboratory bench and the experimental subjects received a score (ranging from 0-normal appearance to 4-highly compromised) for each of these parameters: gait, mobility, breathing, kyphosis, fur, hind limb clasping, tremors, and presence of seizures. The individual scores for each category were subsequently averaged to obtain a semi-quantitative measure of symptom status, called throughout the text “the general health score”. The qualitative evaluation was carried out on the last day of treatment soon after behavioral testing.</p>
</sec>
</sec>
<sec id="sec2dot5-jcm-09-01669">
<title>2.5. Mitochondrial Analyses</title>
<p>At the end of behavioral testing, brains were collected to evaluate whether metformin treatment was able to rescue the reduced mitochondrial ATP production via OXPHOS and restore the alterations in the activity of the MRC complexes and of ATP synthase, the molecular machinery responsible for the majority of cell energy production.</p>
<sec id="sec2dot5dot1-jcm-09-01669">
<title>2.5.1. Brain Tissue Dissection and Mitochondria Isolation</title>
<p>The brains of experimental mice (WT, sal; WT, met; RTT, sal; RTT, met; N = 3 per group) were dissected into two hemispheres and cryopreserved in an ice-cold solution consisting of 50 mM K-Mes (pH = 7.1), 3 mM K<sub>2</sub>HPO<sub>4</sub>, 9.5 mM MgCl<sub>2</sub>, 3 mM ATP plus 20% glycerol and 10 mg/mL bovine serum albumin (BSA) and stored at −80 °C until assay. Mitochondria were isolated from cryopreserved tissues by differential centrifugation of brain homogenate as previously described [<xref ref-type="bibr" rid="B41-jcm-09-01669">41</xref>] and controls were made for checking mitochondrial integrity and function, as reported in [<xref ref-type="bibr" rid="B41-jcm-09-01669">41</xref>].</p>
</sec>
<sec id="sec2dot5dot2-jcm-09-01669">
<title>2.5.2. Mitochondrial ATP Production via OXPHOS</title>
<p>The rate of ATP production by OXPHOS was determined in mitochondria isolated from cryopreserved brain tissues essentially as previously described [<xref ref-type="bibr" rid="B42-jcm-09-01669">42</xref>]. Briefly, mitochondria isolated from total brain (0.5 mg protein) were incubated at 37 °C in 2 mL of respiratory medium consisting of 210 mM mannitol, 70 mM sucrose, 20 mM Tris-HCl, 5 mM KH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub>, (pH = 7.4) plus 5 mg/mL BSA, 3 mM MgCl<sub>2</sub>, in the presence of the ATP detecting system consisting of glucose (2.5 mM), hexokinase (HK, 2 e.u.), glucose 6-phosphate dehydrogenase (G6P-DH, 1 e.u.) and NADP<sup>+</sup> (0.25 mM) by adding glutamate plus malate (GLU/MAL, 5 mM each) or succinate (SUCC, 5 mM) plus rotenone (ROT, 3 mM), or ascorbate (ASC, 0.5 mM) plus N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD, 0.25 mM), as energy sources. The reduction of NADP<sup>+</sup> in the extramitochondrial phase, which reveals ATP formation from externally added ADP (0.5 mM), was monitored as an increase in absorbance at 340 nm. Care was taken to use enough HK/G6P-DH coupled enzymes to ensure a non-limiting ADP-regenerating system for the measurement of ATP production.</p>
</sec>
<sec id="sec2dot5dot3-jcm-09-01669">
<title>2.5.3. Mouse Brain ATP Levels</title>
<p>The brains of experimental subjects (WT, sal; WT, met; RTT, sal; RTT, met; N = 3 per group) were subjected to perchloric acid extraction as described in [<xref ref-type="bibr" rid="B43-jcm-09-01669">43</xref>]. In brief, tissues were homogenized in 600 mL of pre-cooled 10% perchloric acid and then centrifuged at 14,000× <italic>g</italic> for 10 min, 4 °C. The amount of tissue ATP was determined enzymatically in KOH-neutralized extracts, as described in [<xref ref-type="bibr" rid="B42-jcm-09-01669">42</xref>].</p>
</sec>
<sec id="sec2dot5dot4-jcm-09-01669">
<title>2.5.4. MRC Complex Activities</title>
<p>The MRC complex activities were measured spectrophotometrically in mitochondrial membrane-enriched fractions obtained from mitochondria isolated from cryopreserved brain tissues. For isolation of mitochondrial membrane-enriched fractions, mitochondrial pellets were first frozen at −80 °C, then thawed at 2–4 °C, suspended in 1 mL of 10 mM Tris-HCl (pH 7.5) plus 1 mg/mL BSA and exposed to ultrasound energy for 8 s at 0 °C (11 pulses 0.7 s on, 0.7 s off) at 20 kHz, intensity 2. The ultrasound-treated mitochondria were centrifuged at 600× <italic>g</italic> for 10 min, 4 °C. The supernatant was centrifuged again at 14,000× <italic>g</italic> for 10 min at 4 °C and the resulting pellet was kept at −80 °C until use. Measurement of MRC complex activities was performed essentially as in [<xref ref-type="bibr" rid="B44-jcm-09-01669">44</xref>], by two assays which rely on the sequential addition of reagents to measure the activities of complexes I, II, and V (ATPase).</p>
</sec>
</sec>
<sec id="sec2dot6-jcm-09-01669">
<title>2.6. Oxidative Stress Status Analyses</title>
<p>On the blood and the brain of the experimental mice collected 24 hours after the last injection, we also explored metformin treatment effects on the circulating levels of ROS and the oxidative brain damage that occurs in the RTT mouse model.</p>
<sec id="sec2dot6dot1-jcm-09-01669">
<title>2.6.1. ROS Levels in Whole Blood by Electron Paramagnetic Resonance (EPR)</title>
<p>Whole blood of the experimental subjects was collected into heparinized tubes at sacrifice to evaluate ROS levels (WT, sal; WT, met; RTT, sal; RTT, met; N = 3–4 per group). The oxidation of the spin probe 1-hydroxy-3-carboxypyrrolidine (CPH, dissolved in degassed phosphate buffer, pH 7.4, and extensively treated with Chelex-100 to avoid metal contamination) to the correspondent 3-carboxy-proxyl radical (CP<sup>•</sup>) [<xref ref-type="bibr" rid="B45-jcm-09-01669">45</xref>] was monitored by EPR. The formation of CP<sup>•</sup> is not specific to a singular oxidant, but it is suitable to screen the totality of ROS (among which O2<sup>•, •</sup>OH, peroxynitrite, transition metal-catalyzed reactions) produced in biological samples. If the intensity of CP<sup>•</sup> is significantly increased, the presence of a pro-oxidant status is suggested.</p>
<p>Briefly, CPH (0.5 mM) was added to 100 μL whole blood of WT or RTT mice and the intensity of CP<sup>•</sup> was measured after 20 min at 37 °C. Samples were drawn up into a gas-permeable Teflon tube with 0.81-mm internal diameter and 0.05-mm wall thickness (Zeuss Industrial Products). The Teflon tube was folded four times, inserted into a quartz tube, and fixed to the cavity (4108 TMH) of a Bruker ECS 106 EPR spectrometer equipped with a variable temperature unit (ER4111VT). Spectrometer conditions were: modulation frequency, 100 kHz; microwave frequency, 9.4 GHz; microwave power, 20 mW; gain 1 × 104; modulation amplitude, 1G; conversion time, 20.5 ms; time constant, 82 ms; sweep time, 21 s; and number of scans, 1.</p>
</sec>
<sec id="sec2dot6dot2-jcm-09-01669">
<title>2.6.2. Total 4-hydroxy-2-trans-nonenal Protein Bound (HNE-Adducts) in RTT Mouse Brain</title>
<p>To evaluate protein oxidative damage in RTT mouse hippocampus and metformin treatment effects thereon, we investigated hippocampal levels of HNE-adducts, one of the most abundant and toxic aldehydes generated through ROS-mediated peroxidation of lipids [<xref ref-type="bibr" rid="B46-jcm-09-01669">46</xref>]. Hippocampi (WT, sal; WT, met; RTT, sal; RTT, met; N = 9–11 per group) were homogenized and Western blot analyses were performed as described below. The resulting blot was incubated overnight at 4°C with HNE polyclonal antibody (1:2000, Novus Biologicals, Abingdon, UK, #NB100-63093). Next day, the membrane was incubated for 1 h at room temperature with anti-goat horseradish peroxidase-conjugated secondary antibody (A4187, 1:3000) furnished by Sigma-Aldrich (St Louis, MO, USA). The blot was then imaged via the ChemiDoc MP imaging system using Chemiluminescence settings. Subsequent determination of relative abundance via total protein normalization was calculated using Image Lab 6.0 software (Bio-Rad Laboratories Hercules, CA, USA).</p>
</sec>
</sec>
<sec id="sec2dot7-jcm-09-01669">
<title>2.7. Western Blot Analyses</title>
<p>To uncover the molecular mechanisms leading to the improved mitochondrial bioenergetics in metformin treated RTT mouse brain, we next analyzed MRC protein content and the levels of specific targets of metformin by western blotting analysis. To this aim, hippocampi (WT, sal; WT, met; RTT, sal; RTT, met; N = 9–11 per group) were homogenized in RIPA buffer (pH = 7.4) containing 50 mM Tris-HCl (pH = 7.4), 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate,1mM EDTA, 0,1% SDS, 1mM PMSF, 1 mM NaF and 1 mM Na3VO4. Brains were homogenized by 20 strokes of a Wheaton tissue homogenizer and centrifuged at 14,000× <italic>g</italic> 4 °C for 10 min to remove cellular debris. Supernatants were collected to determine total protein concentrations by the BCA method (Pierce, Rockford, IL, USA). Western blots were performed as previously described in [<xref ref-type="bibr" rid="B47-jcm-09-01669">47</xref>]. Briefly, 15 μg of proteins were separated via SDS-PAGE and transferred to a nitrocellulose membrane by Trans-Blot Turbo Transfer System (Bio-Rad Laboratories Hercules, CA, USA). The blot was imaged by ChemiDoc MP imaging system (Bio-Rad Laboratories Hercules, CA, USA) using the Stain-Free Blot settings. Protein total load captured by Stain-Free Blot technology was later used for total protein normalization. Following, the membrane was blocked with 3% of bovine serum albumin (SERVA Electrophoresis GmbH, Heidelberg, Germany) in TBS solution containing 0.01% Tween 20 and incubated overnight at 4 °C with the following primary antibodies: p<sup>Ser40</sup>Nrf2 (Ab76026, 1:3000), Total OXPHOS (Ab110411, 1:3000) from Abcam (Cambridge, UK), MFN2 (#9482, 1:1000) from Cell Signaling Technology (Danvers, MA, USA), HO-1 (ADI-SPA-895, 1:1000), Nrf2 (ADI-KAP-TF125, 1:1000) from Enzo Life Sciences (Farmingdale, NY, USA), NDUFB8 (NBP2-75586, 1:5000) from Novus Biological, PGC-1α (SC-13067, 1:1000), mtTFA (SC-166965, 1:1000) from Santa Cruz Biotechnology (Palo Alto, CA, USA), OPA1 (612607, 1:1000) from BD Transduction Laboratories (San Jose, CA, USA). Next day, all membranes were incubated for 1 h at room temperature with respective horseradish peroxidase-conjugated secondary antibodies: anti-rabbit (L005661; 1:10000), anti-mouse (L005662; 1:10000) from Bio-Rad Laboratories (Hercules, CA, USA). The blot was then imaged via the ChemiDoc MP imaging system using Chemiluminescence settings. Subsequent determination of relative abundance via total protein normalization was calculated using Image Lab 6.0 software (Bio-Rad Laboratories, Hercules, CA, USA).</p>
</sec>
<sec id="sec2dot8-jcm-09-01669">
<title>2.8. Statistical Analyses</title>
<p>Data were analyzed with two-way Analysis of Variance (ANOVA) including genotype (WT vs RTT) and treatment (sal vs met) as independent variables (between-subject factors). Experimental subjects identified as outliers by the use of the Grubbs’ test were excluded from the analyses. <italic>Post hoc</italic> comparisons were performed by Tukey’s test. Results of two-way ANOVA analyses and <italic>post hoc</italic> tests are reported in <xref ref-type="app" rid="app1-jcm-09-01669">Supplementary Table S1</xref>.</p>
</sec>
</sec>
<sec id="sec3-jcm-09-01669" sec-type="results">
<title>3. Results</title>
<sec id="sec3dot1-jcm-09-01669">
<title>3.1. A 10-Day Long Metformin Treatment at 100 mg/kg Dose Rescues the Aberrant Mitochondrial Bioenergetics in the Brain of RTT Mice</title>
<p>To evaluate if a 10-day long metformin treatment can ameliorate the defective bioenergetic efficiency in RTT mouse brain, mitochondrial ATP synthesis and whole-brain ATP levels were measured. As expected, based on previous reports [<xref ref-type="bibr" rid="B19-jcm-09-01669">19</xref>,<xref ref-type="bibr" rid="B20-jcm-09-01669">20</xref>], RTT mice showed a significant reduction in mitochondrial ATP synthesis when succinate, the respiratory substrate of complex II, was provided as energy source (p &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f001">Figure 1</xref>a). ATP levels in the whole brain of RTT mice were also decreased in comparison to WT controls ( p &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f001">Figure 1</xref>b). A complete normalization to WT values of both parameters was found in the brain of metformin-injected RTT mice (p &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f001">Figure 1</xref>a,b).</p>
<p>We previously demonstrated that aberrant mitochondrial bioenergetics in the whole brain of RTT mice is accompanied by alterations in the activity of MRC II and V, in the absence of changes in the activity of MRC I, III and IV [<xref ref-type="bibr" rid="B19-jcm-09-01669">19</xref>,<xref ref-type="bibr" rid="B20-jcm-09-01669">20</xref>]. We thus wondered whether metformin has improved these defects, thus normalizing mitochondrial ATP production in RTT mouse brain. We confirmed a significant reduction in the activity of both complexes in RTT mouse brain compared to WT controls (Complex II: <italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f002">Figure 2</xref>b; Complex V: <italic>p</italic> &lt; 0.05; <xref ref-type="fig" rid="jcm-09-01669-f002">Figure 2</xref>c). Metformin treatment increased complex II and V activity thus restoring WT-like levels (<italic>p</italic> &lt; 0.01 and <italic>p</italic> &lt; 0.05; <xref ref-type="fig" rid="jcm-09-01669-f002">Figure 2</xref>b,c). To confirm that metformin treatment does not affect complex I activity in mouse brain [<xref ref-type="bibr" rid="B10-jcm-09-01669">10</xref>], we extended the analysis to this complex (<xref ref-type="fig" rid="jcm-09-01669-f002">Figure 2</xref>a). In line with previous studies [<xref ref-type="bibr" rid="B19-jcm-09-01669">19</xref>], no significant differences in the activity of complex I were found between WT and RTT mice in whole brain and metformin treatment did not significantly affect this parameter. </p>
<p>Previous data demonstrated that MRC dysfunctions are accompanied by a reduction of specific complex subunits protein levels in mitochondria isolated from RTT mouse cortex and hippocampus [<xref ref-type="bibr" rid="B19-jcm-09-01669">19</xref>]. A similar profile, even though less pronounced, was found in RTT homogenized hippocampi. A significant reduction of SDHB (Complex II: 45% of WT; <italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f003">Figure 3</xref>c) and of UQCRC2 (Complex III: 24% of WT; <italic>p</italic> &lt; 0.05; <xref ref-type="fig" rid="jcm-09-01669-f003">Figure 3</xref>d) were in fact evident in RTT compared to WT group. ATP5A levels (Complex V) appeared reduced as well (27% of WT). This genotype difference did however miss statistical significance (<italic>p</italic> = 0.146; <xref ref-type="fig" rid="jcm-09-01669-f003">Figure 3</xref>f). No genotype differences were observed concerning the levels of NDUFB8 (complex I) and MTCO1 (complex IV) (<xref ref-type="fig" rid="jcm-09-01669-f003">Figure 3</xref>b,e) in mouse hippocampus. Importantly, metformin treatment significantly increased the protein content of the MRC complexes whose activity is defective in RTT mouse brain (<xref ref-type="fig" rid="jcm-09-01669-f003">Figure 3</xref>c,f, SDHB (complex II) and ATP5A (complex V): <italic>p</italic> &lt; 0.01 and <italic>p</italic> &lt; 0.05), thus restoring WT-like levels. No significant treatment effects were found for the other MRC complexes. Metformin treatment thus normalized both the activity and the complex subunits protein levels of complex II and V in RTT mouse brain.</p>
</sec>
<sec id="sec3dot2-jcm-09-01669">
<title>3.2. RTT Female Mice Show an Increased Oxidative Stress Status that Is Restored by Metformin both in the Brain and in the Blood</title>
<p>We next considered whether the treatment with metformin can rescue the aberrant oxidative stress status that occurs in RTT [<xref ref-type="bibr" rid="B25-jcm-09-01669">25</xref>,<xref ref-type="bibr" rid="B48-jcm-09-01669">48</xref>,<xref ref-type="bibr" rid="B49-jcm-09-01669">49</xref>].</p>
<p>Blood ROS levels, measured as the intensity of formation of CP<sup>•</sup> by EPR, were significantly higher in RTT mice compared to WT controls (<italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f004">Figure 4</xref>a), confirming the occurrence of a pro-oxidant status in RTT mice [<xref ref-type="bibr" rid="B25-jcm-09-01669">25</xref>,<xref ref-type="bibr" rid="B48-jcm-09-01669">48</xref>,<xref ref-type="bibr" rid="B49-jcm-09-01669">49</xref>]. Interestingly, metformin treatment decreased the intensity of CP<sup>•</sup> selectively in the whole blood of RTT mice and normalized this value to the same level of WT controls (<italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f004">Figure 4</xref>a).</p>
<p>In conditions of oxidative stress, proteins are highly vulnerable, and may be the target of a number of modifications that affects their functions [<xref ref-type="bibr" rid="B50-jcm-09-01669">50</xref>]. Formation of adducts with lipid peroxidation can be detected as index of tissue-specific damage. Consistently, we found an increase of protein-HNE-adducts in RTT mouse hippocampus compared to WT controls (<italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f004">Figure 4</xref>c), confirming the occurrence of brain oxidative damage in RTT [<xref ref-type="bibr" rid="B26-jcm-09-01669">26</xref>]. Such an increase of protein oxidation was rescued by metformin treatment (<italic>p</italic> &lt; 0.05; <xref ref-type="fig" rid="jcm-09-01669-f004">Figure 4</xref>c).</p>
</sec>
<sec id="sec3dot3-jcm-09-01669">
<title>3.3. Metformin Systemic Treatment Boosts Pathways Related to Mitochondrial Biogenesis and Remodelling in the Brain of RTT Mice</title>
<p>To shed light on the mechanisms leading to the beneficial effects of metformin on brain mitochondrial alterations, we analyzed the expression of PGC-1α and of its downstream target transcription factor A (mtTFA), transcriptional coactivators of mitochondria-related genes [<xref ref-type="bibr" rid="B51-jcm-09-01669">51</xref>] that play key roles in mitochondrial biogenesis [<xref ref-type="bibr" rid="B14-jcm-09-01669">14</xref>]. We focused on this signaling pathway, based on previous studies demonstrating that metformin promotes its activation [<xref ref-type="bibr" rid="B14-jcm-09-01669">14</xref>]. Intriguingly, we found an increase of PGC-1α protein expression levels in the hippocampus of RTT mice compared to WT (<italic>p</italic> &lt; 0.05; <xref ref-type="fig" rid="jcm-09-01669-f005">Figure 5</xref>b) and a corresponding increase of its downstream target mtTFA (<italic>p</italic> &lt; 0.05; <xref ref-type="fig" rid="jcm-09-01669-f005">Figure 5</xref>b). Metformin treatment exacerbated both PGC-1α protein levels (<italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="jcm-09-01669-f005">Figure 5</xref>b) as well as protein expression of its target mtTFA (treatment: <italic>p</italic> = 0.003). </p>
<p>Metformin has been also demonstrated to activate the core machinery that governs the dynamic mitochondrial remodeling, through the induction of proteins that regulate fusion, namely the inner mitochondrial membrane GTPase Optic Atrophy 1 (OPA1) and the outer mitochondrial membrane fusion GTPases Mitofusin 2 (MFN2) [<xref ref-type="bibr" rid="B5-jcm-09-01669">5</xref>]. We found that both OPA1 and MNFN2 protein levels were increased selectively in the hippocampus of metformin-treated RTT mice compared to saline groups (OPA1: <italic>p</italic> &lt; 0.05; <xref ref-type="fig" rid="jcm-09-01669-f005">Figure 5</xref>c; MFN2: <italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="jcm-09-01669-f005">Figure 5</xref>d).</p>
</sec>
<sec id="sec3dot4-jcm-09-01669">
<title>3.4. Metformin Systemic Treatment Boosts Pathways Related to the Antioxidant Response in the Brain of RTT Mice</title>
<p>Consistent with its capacity to increase antioxidant protection, metformin also activates the nuclear respiratory factor 2 (Nrf2), a PGC-1α downstream target that increases the expression of the antioxidant protein heme oxygenase-1 (HO-1) and plays a crucial role in defense mechanisms against cellular oxidative stress [<xref ref-type="bibr" rid="B15-jcm-09-01669">15</xref>,<xref ref-type="bibr" rid="B16-jcm-09-01669">16</xref>,<xref ref-type="bibr" rid="B52-jcm-09-01669">52</xref>]. To verify whether activation of this signaling pathway may account for metformin beneficial effects on the increased oxidative stress status in RTT, we analyzed total levels of Nrf2 and of HO-1 in the hippocampus of the experimental mice. Phosphorylation of Nrf2 at Ser40 was also evaluated as an index of its activation status. In fact, under physiological conditions Nrf2 is maintained in an inactive state by Kelch ECH associating protein 1 (Keap1), but when phosphorylated Nrf2 separates from Keap1 and translocates into the nucleus to induce transcription of HO-1 and other antioxidant factors. We found that treatment with metformin induced a consistent increase of Nrf2 expression in RTT mice (<italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f006">Figure 6</xref>b) and, more importantly, it also promoted its phosphorylation (<italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="jcm-09-01669-f006">Figure 6</xref>b). The increased phosphorylation of Nrf2 was accompanied by an increased transcription and subsequent translation of HO-1 in metformin-treated RTT mouse brain (<italic>p</italic> &lt; 0.05; <xref ref-type="fig" rid="jcm-09-01669-f006">Figure 6</xref>c), thus confirming enhanced metformin-induced Nrf2 nuclear import in RTT mouse hippocampus.</p>
</sec>
<sec id="sec3dot5-jcm-09-01669">
<title>3.5. A 10-Day Long Treatment with Metformin at 100 mg/kg Dose Does Not Improve Behavioral Alterations in RTT Female Mice at an Advanced Stage of the Disease</title>
<p>To assess whether the metformin treatment could rescue motor dysfunction and the compromised general health status of RTT female mice, a battery of behavioral tests was carried out 24 hours after the last systemic treatment with metformin or saline. </p>
<p>The evaluation of the general health status of the experimental mice confirmed that RTT mice show significant phenotypic alterations compared to WT controls (<xref ref-type="fig" rid="jcm-09-01669-f007">Figure 7</xref>a, genotype: <italic>p</italic> = 0.006). The metformin treatment did not affect these parameters in either WT or RTT mice (<xref ref-type="fig" rid="jcm-09-01669-f007">Figure 7</xref>a). The open field and the dowel tests were applied to assess locomotor activity and coordination and balance, respectively. No significant differences in locomotion were highlighted among groups in the open field test, measured as the total distance travelled (<xref ref-type="fig" rid="jcm-09-01669-f007">Figure 7</xref>b). However, all the experimental mice treated with metformin tended to move less in the arena compared to those treated with saline. This difference just missed the statistical significance (<xref ref-type="fig" rid="jcm-09-01669-f007">Figure 7</xref>b). An impaired motor coordination of RTT female mice was confirmed in the dowel test. Indeed, RTT mice fell off the dowel earlier compared with WT mice (<xref ref-type="fig" rid="jcm-09-01669-f007">Figure 7</xref>c). Metformin treatment did not exert any effect on the motor coordination of the experimental subjects (<xref ref-type="fig" rid="jcm-09-01669-f007">Figure 7</xref>c).</p>
</sec>
</sec>
<sec id="sec4-jcm-09-01669" sec-type="discussion">
<title>4. Discussion</title>
<p>The present study evaluated the possibility to repurpose the anti-diabetic drug metformin for RTT, a severe neurologic disorder characterized by behavioral, physiological as well as metabolic alterations, for which no cure currently exists. Present findings provide innovative evidence that alterations in brain mitochondrial bioenergetics, the oxidative stress status, and the antioxidant defense can be profoundly improved by metformin in a female mouse model of RTT at an advanced stage of the disease.</p>
<p>Increasing evidence demonstrates that besides its well-known antihyperglycemic action, metformin exerts pleiotropic effects, providing a general improvement of cellular energetics, even in the brain [<xref ref-type="bibr" rid="B1-jcm-09-01669">1</xref>]. Emerging evidence also points to mitochondria as crucial targets of this clinically approved drug [<xref ref-type="bibr" rid="B11-jcm-09-01669">11</xref>,<xref ref-type="bibr" rid="B12-jcm-09-01669">12</xref>]. These observations have attracted much attention since they have highlighted the possibility to extend the use of metformin to pathologies other than diabetes, including neurologic disorders [<xref ref-type="bibr" rid="B4-jcm-09-01669">4</xref>,<xref ref-type="bibr" rid="B53-jcm-09-01669">53</xref>,<xref ref-type="bibr" rid="B54-jcm-09-01669">54</xref>,<xref ref-type="bibr" rid="B55-jcm-09-01669">55</xref>]. Present findings lie in this direction suggesting that metformin represents an intriguing candidate drug even for RTT. Recent studies in fact support metabolic alterations as key components of RTT pathogenesis, with mouse models and patients showing numerous alterations ranging from lipid metabolism perturbation to mitochondrial abnormalities [<xref ref-type="bibr" rid="B27-jcm-09-01669">27</xref>,<xref ref-type="bibr" rid="B29-jcm-09-01669">29</xref>]. The therapeutic potential for RTT of drugs targeting metabolic dysfunction is however still unclear [<xref ref-type="bibr" rid="B29-jcm-09-01669">29</xref>]. We have previously demonstrated that brain mitochondrial dysfunction in RTT can be rescued by targeting the Rho GTPases family of proteins and this effect is accompanied by a significant improvement of neurobehavioral alterations [<xref ref-type="bibr" rid="B19-jcm-09-01669">19</xref>,<xref ref-type="bibr" rid="B56-jcm-09-01669">56</xref>], suggesting that mitochondria may represent a promising therapeutic target. The applicability in the clinical setting of these molecules is however still under investigation. In this context, we aimed at identifying clinically approved drugs targeting brain mitochondria dysfunction that could be promptly repurposed, thus increasing the translational value of this pharmacological approach. </p>
<p>In spite of the promising results suggesting the therapeutic efficacy of metformin for a plethora of disorders, the molecular details of its mechanism of action are not fully elucidated. Given that transcriptional defects of mitochondrial genes have been demonstrated to occur in RTT, that may account for mitochondrial dysfunction [<xref ref-type="bibr" rid="B24-jcm-09-01669">24</xref>,<xref ref-type="bibr" rid="B49-jcm-09-01669">49</xref>], it is reasonable to hypothesize that the restoration of the reduced protein content and of the activity of MRC complexes by metformin might have rescued mitochondrial bioenergetics alterations in RTT mouse brain. These effects may be achieved through a compensatory boost of the PGC-1α signaling [<xref ref-type="bibr" rid="B14-jcm-09-01669">14</xref>,<xref ref-type="bibr" rid="B57-jcm-09-01669">57</xref>]. Metformin in fact promoted, selectively in RTT mouse hippocampus, a transcriptional up-regulation of PGC-1α downstream target proteins known to stimulate either mitochondrial biogenesis or the organelle remodeling. Interestingly, a similar effect has been previously reported in fibroblasts from DS patients [<xref ref-type="bibr" rid="B5-jcm-09-01669">5</xref>]. Of note, however, a constitutive downregulation of PGC-1α ensues in this cellular model of DS, that has been suggested to contribute to the aberrant mitochondrial functionality. An opposite profile was found in RTT mouse hippocampus, where a reduced protein content of MRC complexes subunits was accompanied by an increase of PGC-1α protein expression levels and a corresponding increase of its downstream target mtTFA, an activator of mitochondrial genes transcription. These results suggest that the induction of mitochondrial biogenesis by PGC-1α may not be sufficient (or sufficiently efficient) to compensate for the bioenergetic alterations in RTT mouse brain. Intriguingly, we found that metformin treatment strongly exacerbated the increase of PGC-1α and mtTFA protein expression levels in RTT mouse brain. Whether these molecular effects may have contributed to the beneficial effects of metformin on RTT-related aberrant mitochondrial functionality certainly needs further investigations. Interestingly, metformin treated RTT mice also showed an induction in the brain expression of OPA1 and MFN2, proteins that regulate dynamic mitochondrial remodeling, suggesting that the simultaneous effect on mitochondrial biogenesis and the organelle remodeling, the two leading mechanisms regulating mitochondrial functionality, may be the key mechanism underlying the beneficial effects of metformin. Further studies addressing treatment effects on the quantity and morphology of mitochondria in RTT mouse brain may help to clarify the actual contribution of the reported molecular effects. </p>
<p>Besides the effects on mitochondrial functionality, one of the key results of this study is the metformin-induced amelioration of the aberrant prooxidant status and of the brain oxidative damage in RTT. Available data suggest that the main mechanism by which metformin reduces mitochondrial ROS production and improves oxidative stress status is a mild and selective inhibition of the MRC complex I [<xref ref-type="bibr" rid="B58-jcm-09-01669">58</xref>]. Nevertheless, the impact that metformin has on cellular energy homeostasis is tissue-specific and the investigation of its action in the brain is far from complete and still a challenge in biguanide research [<xref ref-type="bibr" rid="B1-jcm-09-01669">1</xref>]. Herein, we demonstrate that metformin had no effects on complex I activity in mouse brain. We did however find that metformin stimulates the PGC-1α/Nrf2/HO-1 signaling pathway selectively in RTT mouse brain. Indeed, previous works suggested that alterations in the activation of Nrf2 may be responsible for the increased oxidative stress in RTT [<xref ref-type="bibr" rid="B59-jcm-09-01669">59</xref>]. In fact, the stimulation of PGC-1α/Nrf2 pathway is known to boost the expression of fundamental mitochondrial antioxidant genes, preventing oxidative injury and mitochondrial dysfunction [<xref ref-type="bibr" rid="B60-jcm-09-01669">60</xref>]. Present results provide support to this hypothesis by demonstrating that stimulation of the expression and nuclear import of Nrf2 by metformin and the consequent transcription of genes that regulate the antioxidant defense, such as HO-1, selectively in RTT mouse brain was accompanied by an improvement of the oxidative stress status. </p>
<p>Interestingly, metformin treatment did not boost pathways related to mitochondrial biogenesis and antioxidant response in WT mice. Indeed, previous studies have demonstrated that metformin’s effects on mitochondrial dynamics are strictly dependent on the initial bioenergetic status [<xref ref-type="bibr" rid="B8-jcm-09-01669">8</xref>]. How metformin adapts its effects is however still unclear. Our results lie in the same direction and suggest that PGC-1α dependent pathways may play a crucial role in mediating metformin differential effects on bioenergetic alterations.</p>
<p>Importantly, acute injections of the 200 mg/kg dose of metformin in our study did induce convulsions, thus leading us to test the efficacy of the 100 mg/kg dose. The higher initial dose of metformin was chosen as it provides beneficial effects in a mouse model of Fragile X [<xref ref-type="bibr" rid="B4-jcm-09-01669">4</xref>], a disorder with many symptoms in common with RTT. As the main difference from the Fragile X study concerns the age of the animals (two months vs about 1 year in the present study), it is conceivable that the 200 mg/kg may have provided convulsions in both WT and RTT mice due to their advanced age. Consistently, previous studies have demonstrated that metformin exerts different effects depending on the age of the mice [<xref ref-type="bibr" rid="B8-jcm-09-01669">8</xref>]. Furthermore, Martin-Montalvo and colleagues [<xref ref-type="bibr" rid="B6-jcm-09-01669">6</xref>] similarly observed that chronic high doses of metformin in old mice can be toxic. Present results stress the need to further investigate metformin dose-dependent effects during aging. </p>
<p>Contrary to our expectations, metformin induced improvements in mitochondrial bioenergetics and oxidative stress status were not accompanied by the rescue of health conditions and motor dysfunction in RTT mice. Present data may challenge the pathogenic role of mitochondrial dysfunction for RTT and suggest that targeting brain mitochondrial dysfunction may not be the correct therapeutic strategy for this disorder. We cannot however exclude that the lack of beneficial effects on the behavioral phenotype of a 10-day long treatment with metformin in RTT mice may be due to the short duration of the treatment or the advanced age of the experimental subjects. Several studies have in fact demonstrated that mitochondrial dysfunction may precede the establishment of behavioral symptoms [<xref ref-type="bibr" rid="B50-jcm-09-01669">50</xref>]. Given the essential role of mitochondrial function in mediating neurogenesis and neural circuits rearrangement [<xref ref-type="bibr" rid="B61-jcm-09-01669">61</xref>,<xref ref-type="bibr" rid="B62-jcm-09-01669">62</xref>], it is conceivable that an early treatment with metformin could rescue the aberrant neurodevelopment in RTT mice and may produce better outcomes on RTT-related behavioral alterations. It is also plausible that the restoration of aberrant brain bioenergetics and oxidative status for more than 10 days may be needed for a neurologic improvement to occur at a fully symptomatic stage of the disease. </p>
<p>Normalization of impaired performances represents the most attractive outcome in a translational context. Further studies are thus certainly needed aimed at testing whether a pharmacological intervention with metformin during specific time windows of neurodevelopment or a longer administration schedule once symptoms are already established can prevent disease onset or provide beneficial effects on the neurobehavioral alterations in RTT mice. Since accumulated damage to mitochondria acts as a key factor underlying cognitive deficits which are reported as one of the most debilitating symptoms in RTT, a more in-depth examination of metformin effects on learning and memory is also needed to completely verify metformin efficacy.</p>
<p>Taken together, present results provide preclinical evidence that significant improvements in mitochondrial dysfunction and oxidative stress status alterations can be achieved in fully symptomatic RTT mice by treatment with metformin (<xref ref-type="fig" rid="jcm-09-01669-f008">Figure 8</xref>), a drug which could be promptly repurposed, even in pediatric patients [<xref ref-type="bibr" rid="B63-jcm-09-01669">63</xref>]. Even though further studies are needed to uncover the underlying molecular mechanisms and the most suitable time window for metformin administration, this study suggests that RTT patients may benefit from metformin administration, thus opening a new window of therapeutic opportunities for this severe and untreatable disorder.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors are grateful to Daniele Vigli, Maria Cristina Talamo and Mattia Pellas for technical assistance. Nadia Francia and Stella Falsini for administrative assistance.</p>
</ack>
<app-group>
<app id="app1-jcm-09-01669">
<title>Supplementary Materials</title>
<p>The following are available online at <uri xlink:href="https://www.mdpi.com/2077-0383/9/6/1669/s1">https://www.mdpi.com/2077-0383/9/6/1669/s1</uri>, Table S1: Summary of two-way ANOVA analyses and <italic>post hoc</italic> tests of all the results, Figure S1: Full Immunoblot of Western blot results.</p>
<supplementary-material content-type="local-data" id="jcm-09-01669-s001">
<media xlink:href="jcm-09-01669-s001.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</app>
</app-group>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, F.D.D., M.P., R.A.V. and B.D.F.; Formal analysis, I.Z., C.U. and L.C.; Funding acquisition, B.D.F.; Investigation, I.Z., D.V., M.C.Q., V.M., L.C. and D.P.; Methodology, I.Z., D.V., V.M., D.P., F.D.D., M.P., R.A.V. and B.D.F.; Project administration, B.D.F.; Resources, D.P., F.D.D., M.P., R.A.V. and B.D.F.; Supervision, D.P., F.D.D., M.P., R.A.V. and B.D.F.; Validation, D.P., F.D.D., M.P., R.A.V. and B.D.F.; Writing – original draft, I.Z., C.U. and B.D.F.; Writing – review &amp; editing, I.Z., C.U., D.V., M.C.Q., V.M., L.C., D.P., F.D.D., M.P., R.A.V. and B.D.F. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This study was supported by the Italian Ministry of Health (#GR-2018-12366210) to B.D.F.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-jcm-09-01669">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foretz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guigas</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pollak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Viollet</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Metformin: From mechanisms of action to therapies</article-title>
<source/>Cell Metab.
          <year>2014</year>
<volume>20</volume>
<fpage>953</fpage>
<lpage>956</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2014.09.018</pub-id>
<pub-id pub-id-type="pmid">25456737</pub-id>
</element-citation>
</ref>
<ref id="B2-jcm-09-01669">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pryor</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cabreiro</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Repurposing metformin: An old drug with new tricks in its binding pockets</article-title>
<source/>Biochem. J.
          <year>2015</year>
<volume>471</volume>
<fpage>307</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20150497</pub-id>
<pub-id pub-id-type="pmid">26475449</pub-id>
</element-citation>
</ref>
<ref id="B3-jcm-09-01669">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heckman-Stoddard</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>DeCensi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sahasrabuddhe</surname>
<given-names>V.V.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>L.G.</given-names>
</name>
</person-group>
<article-title>Repurposing metformin for the prevention of cancer and cancer recurrence</article-title>
<source/>Diabetologia
          <year>2017</year>
<volume>60</volume>
<fpage>1639</fpage>
<lpage>1647</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-017-4372-6</pub-id>
<pub-id pub-id-type="pmid">28776080</pub-id>
</element-citation>
</ref>
<ref id="B4-jcm-09-01669">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gantois</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Khoutorsky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Popic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aguilar-Valles</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Freemantle</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pooters</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nagpal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Skalecka</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metformin ameliorates core deficits in a mouse model of fragile X syndrome</article-title>
<source/>Nat. Med.
          <year>2017</year>
<volume>23</volume>
<fpage>674</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="doi">10.1038/nm.4335</pub-id>
<pub-id pub-id-type="pmid">28504725</pub-id>
</element-citation>
</ref>
<ref id="B5-jcm-09-01669">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nitti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mollo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Paladino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Procaccini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Faicchia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Calì</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Genesio</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bonfiglio</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cicatiello</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in Down syndrome cells</article-title>
<source/>Hum. Mol. Genet.
          <year>2017</year>
<volume>26</volume>
<fpage>1056</fpage>
<lpage>1069</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddx016</pub-id>
<pub-id pub-id-type="pmid">28087733</pub-id>
</element-citation>
</ref>
<ref id="B6-jcm-09-01669">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin-Montalvo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mercken</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Palacios</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Mote</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Scheibye-Knudsen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Minor</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Blouin</surname>
<given-names>M.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metformin improves healthspan and lifespan in mice</article-title>
<source/>Nat. Commun.
          <year>2013</year>
<volume>4</volume>
<fpage>2192</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms3192</pub-id>
<pub-id pub-id-type="pmid">23900241</pub-id>
</element-citation>
</ref>
<ref id="B7-jcm-09-01669">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alcocer-Gomez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Garrido-Maraver</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bullón</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marín-Aguilar</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cotán</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Carrión</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Alvarez-Suarez</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Giampieri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sánchez-Alcazar</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Battino</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metformin and caloric restriction induce an AMPK-dependent restoration of mitochondrial dysfunction in fibroblasts from Fibromyalgia patients</article-title>
<source/>Biochim. Biophys. Acta
          <year>2015</year>
<volume>1852</volume>
<fpage>1257</fpage>
<lpage>1267</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2015.03.005</pub-id>
<pub-id pub-id-type="pmid">25779083</pub-id>
</element-citation>
</ref>
<ref id="B8-jcm-09-01669">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sivayoganathan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Abdullahi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Parousis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Jeschke</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Metformin adapts its cellular effects to bioenergetic status in a model of metabolic dysfunction</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>5646</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-24017-7</pub-id>
<pub-id pub-id-type="pmid">29618839</pub-id>
</element-citation>
</ref>
<ref id="B9-jcm-09-01669">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kane</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>J.W.</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Woodlief</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Bikman</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Cortright</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Neufer</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>Metformin selectively attenuates mitochondrial H<sub>2</sub>O<sub>2</sub> emission without affecting respiratory capacity in skeletal muscle of obese rats</article-title>
<source/>Free Radic. Biol. Med.
          <year>2010</year>
<volume>49</volume>
<fpage>1082</fpage>
<lpage>1087</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.06.022</pub-id>
<pub-id pub-id-type="pmid">20600832</pub-id>
</element-citation>
</ref>
<ref id="B10-jcm-09-01669">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruegsegger</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Vanderboom</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Dasari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Klaus</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Kabiraj</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Lucchinetti</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>K.S.</given-names>
</name>
</person-group>
<article-title>Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain</article-title>
<source/>JCI Insight
          <year>2019</year>
<volume>4</volume>
<fpage>e130681</fpage>
<pub-id pub-id-type="doi">10.1172/jci.insight.130681</pub-id>
</element-citation>
</ref>
<ref id="B11-jcm-09-01669">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecinova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brázdová</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Drahota</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Houštěk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mráček</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Mitochondrial targets of metformin—Are they physiologically relevant?</article-title>
<source/>Biofactors
          <year>2019</year>
<volume>45</volume>
<fpage>703</fpage>
<lpage>711</lpage>
<pub-id pub-id-type="doi">10.1002/biof.1548</pub-id>
<pub-id pub-id-type="pmid">31343786</pub-id>
</element-citation>
</ref>
<ref id="B12-jcm-09-01669">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vial</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Detaille</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Guigas</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Role of mitochondria in the mechanism(s) of action of metformin</article-title>
<source/>Front. Endocrinol.
          <year>2019</year>
<volume>10</volume>
<fpage>294</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2019.00294</pub-id>
<pub-id pub-id-type="pmid">31133988</pub-id>
</element-citation>
</ref>
<ref id="B13-jcm-09-01669">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fontaine</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Metformin-induced mitochondrial complex i inhibition: Facts, uncertainties, and consequences</article-title>
<source/>Front. Endocrinol.
          <year>2018</year>
<volume>9</volume>
<fpage>753</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2018.00753</pub-id>
<pub-id pub-id-type="pmid">30619086</pub-id>
</element-citation>
</ref>
<ref id="B14-jcm-09-01669">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aatsinki</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Buler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Salomäki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Koulu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pavek</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hakkola</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Metformin induces PGC-1alpha expression and selectively affects hepatic PGC-1alpha functions</article-title>
<source/>Br. J. Pharmacol.
          <year>2014</year>
<volume>171</volume>
<fpage>2351</fpage>
<lpage>2363</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12585</pub-id>
<pub-id pub-id-type="pmid">24428821</pub-id>
</element-citation>
</ref>
<ref id="B15-jcm-09-01669">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashabi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Khodagholi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Khalaj</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Goudarzvand</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nasiri</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: Interference of AMPK/PGC-1alpha pathway</article-title>
<source/>Metab. Brain. Dis.
          <year>2014</year>
<volume>29</volume>
<fpage>47</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1007/s11011-013-9475-2</pub-id>
<pub-id pub-id-type="pmid">24435937</pub-id>
</element-citation>
</ref>
<ref id="B16-jcm-09-01669">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nioi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sherratt</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pickett</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation</article-title>
<source/>Mol. Cell. Biol.
          <year>2005</year>
<volume>25</volume>
<fpage>10895</fpage>
<lpage>10906</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.25.24.10895-10906.2005</pub-id>
<pub-id pub-id-type="pmid">16314513</pub-id>
</element-citation>
</ref>
<ref id="B17-jcm-09-01669">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valenti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>de Bari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Henrion-Caude</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: An overview of Down syndrome, autism, Fragile X and Rett syndrome</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2014</year>
<volume>46</volume>
<fpage>202</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.01.012</pub-id>
<pub-id pub-id-type="pmid">24548784</pub-id>
</element-citation>
</ref>
<ref id="B18-jcm-09-01669">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chahrour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>MeCP2, a key contributor to neurological disease, activates and represses transcription</article-title>
<source/>Science
          <year>2008</year>
<volume>320</volume>
<fpage>1224</fpage>
<lpage>1229</lpage>
<pub-id pub-id-type="doi">10.1126/science.1153252</pub-id>
<pub-id pub-id-type="pmid">18511691</pub-id>
</element-citation>
</ref>
<ref id="B19-jcm-09-01669">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Valenti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chiodi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ferrante</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>de Bari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fiorentini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Domenici</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Ricceri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Fabbri</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modulation of Rho GTPases rescues brain mitochondrial dysfunction, cognitive deficits and aberrant synaptic plasticity in female mice modeling Rett syndrome</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2015</year>
<volume>25</volume>
<fpage>889</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.03.012</pub-id>
<pub-id pub-id-type="pmid">25890884</pub-id>
</element-citation>
</ref>
<ref id="B20-jcm-09-01669">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Valenti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>de Bari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Rasmo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Musto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fabbri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ricceri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fiorentini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Mitochondrial free radical overproduction due to respiratory chain impairment in the brain of a mouse model of Rett syndrome: Protective effect of CNF1</article-title>
<source/>Free Radic. Biol. Med.
          <year>2015</year>
<volume>83</volume>
<fpage>167</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.02.014</pub-id>
<pub-id pub-id-type="pmid">25708779</pub-id>
</element-citation>
</ref>
<ref id="B21-jcm-09-01669">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gold</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hargreaves</surname>
<given-names>I.P.</given-names>
</name>
<name>
<surname>Land</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Pelka</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Christodoulou</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in the skeletal muscle of a mouse model of Rett syndrome (RTT): Implications for the disease phenotype</article-title>
<source/>Mitochondrion
          <year>2014</year>
<volume>15</volume>
<fpage>10</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.mito.2014.02.012</pub-id>
<pub-id pub-id-type="pmid">24613463</pub-id>
</element-citation>
</ref>
<ref id="B22-jcm-09-01669">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valenti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>de Bari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vigli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lacivita</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Leopoldo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Stimulation of the brain serotonin receptor 7 rescues mitochondrial dysfunction in female mice from two models of Rett syndrome</article-title>
<source/>Neuropharmacology
          <year>2017</year>
<volume>121</volume>
<fpage>79</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.04.024</pub-id>
<pub-id pub-id-type="pmid">28419872</pub-id>
</element-citation>
</ref>
<ref id="B23-jcm-09-01669">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filosa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>D’Esposito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hajek</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome</article-title>
<source/>Free Radic. Biol. Med.
          <year>2015</year>
<volume>88</volume>
<fpage>81</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.04.019</pub-id>
<pub-id pub-id-type="pmid">25960047</pub-id>
</element-citation>
</ref>
<ref id="B24-jcm-09-01669">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leoni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Canali</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cortelazzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ciccoli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genes related to mitochondrial functions, protein degradation, and chromatin folding are differentially expressed in lymphomonocytes of Rett syndrome patients</article-title>
<source/>Mediators Inflamm.
          <year>2013</year>
<volume>2013</volume>
<fpage>137629</fpage>
<pub-id pub-id-type="doi">10.1155/2013/137629</pub-id>
<pub-id pub-id-type="pmid">24453408</pub-id>
</element-citation>
</ref>
<ref id="B25-jcm-09-01669">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Felice</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ciccoli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vannuccini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guazzi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Latini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Comporti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systemic oxidative stress in classic Rett syndrome</article-title>
<source/>Free Radic. Biol. Med.
          <year>2009</year>
<volume>47</volume>
<fpage>440</fpage>
<lpage>448</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.05.016</pub-id>
<pub-id pub-id-type="pmid">19464363</pub-id>
</element-citation>
</ref>
<ref id="B26-jcm-09-01669">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Felice</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Della Ragione</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ciccoli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Scalabrì</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marracino</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Madonna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Belmonte</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome</article-title>
<source/>Neurobiol. Dis.
          <year>2014</year>
<volume>68</volume>
<fpage>66</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2014.04.006</pub-id>
<pub-id pub-id-type="pmid">24769161</pub-id>
</element-citation>
</ref>
<ref id="B27-jcm-09-01669">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kyle</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Vashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Justice</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Rett syndrome: A neurological disorder with metabolic components</article-title>
<source/>Open Biol.
          <year>2018</year>
<volume>8</volume>
<fpage>170216</fpage>
<pub-id pub-id-type="doi">10.1098/rsob.170216</pub-id>
<pub-id pub-id-type="pmid">29445033</pub-id>
</element-citation>
</ref>
<ref id="B28-jcm-09-01669">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kyle</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Justice</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex</article-title>
<source/>Hum. Mol. Genet.
          <year>2016</year>
<volume>25</volume>
<fpage>3029</fpage>
<lpage>3041</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddw156</pub-id>
<pub-id pub-id-type="pmid">27288453</pub-id>
</element-citation>
</ref>
<ref id="B29-jcm-09-01669">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Justice</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Buchovecky</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Kyle</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Djukic</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A role for metabolism in Rett syndrome pathogenesis: New clinical findings and potential treatment targets</article-title>
<source/>Rare Dis.
          <year>2013</year>
<volume>1</volume>
<fpage>e27265</fpage>
<pub-id pub-id-type="doi">10.4161/rdis.27265</pub-id>
<pub-id pub-id-type="pmid">25003017</pub-id>
</element-citation>
</ref>
<ref id="B30-jcm-09-01669">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricceri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Mouse models of Rett syndrome: From behavioural phenotyping to preclinical evaluation of new therapeutic approaches</article-title>
<source/>Behav. Pharmacol.
          <year>2008</year>
<volume>19</volume>
<fpage>501</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="doi">10.1097/FBP.0b013e32830c3645</pub-id>
<pub-id pub-id-type="pmid">18690105</pub-id>
</element-citation>
</ref>
<ref id="B31-jcm-09-01669">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shahbazian</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Rett syndrome and MeCP2: Linking epigenetics and neuronal function</article-title>
<source/>Am. J. Hum. Genet.
          <year>2002</year>
<volume>71</volume>
<fpage>1259</fpage>
<lpage>1272</lpage>
<pub-id pub-id-type="doi">10.1086/345360</pub-id>
<pub-id pub-id-type="pmid">12442230</pub-id>
</element-citation>
</ref>
<ref id="B32-jcm-09-01669">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katz</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Berger-Sweeney</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Eubanks</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Justice</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Neul</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Pozzo-Miller</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Blue</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Giustetto</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preclinical research in Rett syndrome: Setting the foundation for translational success</article-title>
<source/>Dis. Model Mech.
          <year>2012</year>
<volume>5</volume>
<fpage>733</fpage>
<lpage>745</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.011007</pub-id>
<pub-id pub-id-type="pmid">23115203</pub-id>
</element-citation>
</ref>
<ref id="B33-jcm-09-01669">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Genes and sex hormones interaction in neurodevelopmental disorders</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2016</year>
<volume>67</volume>
<fpage>9</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.02.019</pub-id>
<pub-id pub-id-type="pmid">26952805</pub-id>
</element-citation>
</ref>
<ref id="B34-jcm-09-01669">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chiodi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Adriani</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lacivita</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mallozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Leopoldo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Domenici</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Fuso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Long-lasting beneficial effects of central serotonin receptor 7 stimulation in female mice modeling Rett syndrome</article-title>
<source/>Front. Behav. Neurosci.
          <year>2015</year>
<volume>9</volume>
<fpage>86</fpage>
<pub-id pub-id-type="doi">10.3389/fnbeh.2015.00086</pub-id>
<pub-id pub-id-type="pmid">25926782</pub-id>
</element-citation>
</ref>
<ref id="B35-jcm-09-01669">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vigli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Raggi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Woolley-Roberts</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome</article-title>
<source/>Neuropharmacology
          <year>2018</year>
<volume>140</volume>
<fpage>121</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.07.029</pub-id>
<pub-id pub-id-type="pmid">30056123</pub-id>
</element-citation>
</ref>
<ref id="B36-jcm-09-01669">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vigli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Raggi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Woolley-Roberts</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Metformin produces anxiolytic-like effects in rats by facilitating GABAA receptor trafficking to membrane</article-title>
<source/>Br. J. Pharmacol.
          <year>2019</year>
<volume>176</volume>
<fpage>297</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="pmid">30318707</pub-id>
</element-citation>
</ref>
<ref id="B37-jcm-09-01669">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kavelaars</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heijnen</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Metformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0151890</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0151890</pub-id>
<pub-id pub-id-type="pmid">27018597</pub-id>
</element-citation>
</ref>
<ref id="B38-jcm-09-01669">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howell</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Hellberg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Talbott</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kolar</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Hoxhaj</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Saghatelian</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Manning</surname>
<given-names>B.D.</given-names>
</name>
</person-group>
<article-title>Metformin Inhibits Hepatic mTORC1 Signaling via Dose-dependent mechanisms involving AMPK and the TSC complex</article-title>
<source/>Cell Metab.
          <year>2017</year>
<volume>25</volume>
<fpage>463</fpage>
<lpage>471</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2016.12.009</pub-id>
<pub-id pub-id-type="pmid">28089566</pub-id>
</element-citation>
</ref>
<ref id="B39-jcm-09-01669">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ricceri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Early postnatal behavioral changes in the Mecp2-308 truncation mouse model of Rett syndrome</article-title>
<source/>Genes Brain Behav.
          <year>2010</year>
<volume>9</volume>
<fpage>213</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2009.00551.x</pub-id>
<pub-id pub-id-type="pmid">19958389</pub-id>
</element-citation>
</ref>
<ref id="B40-jcm-09-01669">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ricceri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for Rett syndrome</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<volume>39</volume>
<fpage>2506</fpage>
<lpage>2518</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2014.105</pub-id>
<pub-id pub-id-type="pmid">24809912</pub-id>
</element-citation>
</ref>
<ref id="B41-jcm-09-01669">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valenti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>de Bari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ricceri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Preservation of mitochondrial functional integrity in mitochondria isolated from small cryopreserved mouse brain areas</article-title>
<source/>Anal. Biochem.
          <year>2014</year>
<volume>444</volume>
<fpage>25</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.ab.2013.08.030</pub-id>
<pub-id pub-id-type="pmid">24018341</pub-id>
</element-citation>
</ref>
<ref id="B42-jcm-09-01669">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valenti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tullo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Caratozzolo</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Merafina</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Scartezzini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marra</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylate kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy</article-title>
<source/>Biochem. J.
          <year>2010</year>
<volume>431</volume>
<fpage>299</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20100581</pub-id>
<pub-id pub-id-type="pmid">20698827</pub-id>
</element-citation>
</ref>
<ref id="B43-jcm-09-01669">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>H.A.</given-names>
</name>
</person-group>
<article-title>Bioluminometric assay of ATP in mouse brain: Determinant factors for enhanced test sensitivity</article-title>
<source/>J. Biosci.
          <year>2003</year>
<volume>28</volume>
<fpage>379</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1007/BF02705114</pub-id>
<pub-id pub-id-type="pmid">12799486</pub-id>
</element-citation>
</ref>
<ref id="B44-jcm-09-01669">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valenti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Manente</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marra</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: Involvement of the cAMP/PKA signalling pathway</article-title>
<source/>Biochem. J.
          <year>2011</year>
<volume>435</volume>
<fpage>679</fpage>
<lpage>688</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20101908</pub-id>
<pub-id pub-id-type="pmid">21338338</pub-id>
</element-citation>
</ref>
<ref id="B45-jcm-09-01669">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Straface</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Marchesi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gambardella</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Metere</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tarissi de Jacobis</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Viora</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giordani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Villani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Del Principe</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Does oxidative stress play a critical role in cardiovascular complications of Kawasaki disease?</article-title>
<source/>Antioxid. Redox Signal.
          <year>2012</year>
<volume>17</volume>
<fpage>1441</fpage>
<lpage>1446</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2012.4660</pub-id>
<pub-id pub-id-type="pmid">22578402</pub-id>
</element-citation>
</ref>
<ref id="B46-jcm-09-01669">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Domenico</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tramutola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Butterfield, Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders</article-title>
<source/>Free Radic. Biol. Med.
          <year>2017</year>
<volume>111</volume>
<fpage>253</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.10.490</pub-id>
<pub-id pub-id-type="pmid">27789292</pub-id>
</element-citation>
</ref>
<ref id="B47-jcm-09-01669">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tramutola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lanzillotta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Barone</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Arena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zuliani</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mosca</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Blarzino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Perluigi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Domenico</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome</article-title>
<source/>Transl. Neurodegener.
          <year>2018</year>
<volume>7</volume>
<fpage>28</fpage>
<pub-id pub-id-type="doi">10.1186/s40035-018-0133-9</pub-id>
<pub-id pub-id-type="pmid">30410750</pub-id>
</element-citation>
</ref>
<ref id="B48-jcm-09-01669">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grosser</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hirt</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Janc</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Menzfeld</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kempkes</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Vogelgesang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Manzke</surname>
<given-names>T.U.</given-names>
</name>
<name>
<surname>Opitz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Salinas-Riester</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome</article-title>
<source/>Neurobiol. Dis.
          <year>2012</year>
<volume>48</volume>
<fpage>102</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2012.06.007</pub-id>
<pub-id pub-id-type="pmid">22750529</pub-id>
</element-citation>
</ref>
<ref id="B49-jcm-09-01669">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shulyakova</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Andreazza</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Eubanks</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in the pathogenesis of Rett syndrome: Implications for Mitochondria-targeted therapies</article-title>
<source/>Front. Cell. Neurosci.
          <year>2017</year>
<volume>11</volume>
<fpage>58</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2017.00058</pub-id>
<pub-id pub-id-type="pmid">28352216</pub-id>
</element-citation>
</ref>
<ref id="B50-jcm-09-01669">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Domenico</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pupo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tramutola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giorgi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schininà</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Coccia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Head</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Perluigi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: Clues for understanding the development of Alzheimer disease</article-title>
<source/>Free Radic. Biol. Med.
          <year>2014</year>
<volume>71</volume>
<fpage>270</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.03.027</pub-id>
<pub-id pub-id-type="pmid">24675226</pub-id>
</element-citation>
</ref>
<ref id="B51-jcm-09-01669">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virbasius</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Scarpulla</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: A potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1994</year>
<volume>91</volume>
<fpage>1309</fpage>
<lpage>1313</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.91.4.1309</pub-id>
<pub-id pub-id-type="pmid">8108407</pub-id>
</element-citation>
</ref>
<ref id="B52-jcm-09-01669">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Manda</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alcaraz</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Barbas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Daiber</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghezzi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>León</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>López</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Oliva</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach</article-title>
<source/>Pharmacol. Rev.
          <year>2018</year>
<volume>70</volume>
<fpage>348</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="doi">10.1124/pr.117.014753</pub-id>
<pub-id pub-id-type="pmid">29507103</pub-id>
</element-citation>
</ref>
<ref id="B53-jcm-09-01669">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Metformin Alleviated Abeta—Induced Apoptosis via the suppression of JNK MAPK signaling pathway in cultured hippocampal neurons</article-title>
<source/>Biomed. Res. Int.
          <year>2016</year>
<volume>2016</volume>
<fpage>1421430</fpage>
<pub-id pub-id-type="pmid">27403417</pub-id>
</element-citation>
</ref>
<ref id="B54-jcm-09-01669">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Markowicz-Piasecka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sikora</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Szydłowska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Skupień</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mikiciuk-Olasik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>Metformin—A future therapy for neurodegenerative diseases: Theme: Drug discovery, development and delivery in Alzheimer’s disease guest editor: Davide Brambilla</article-title>
<source/>Pharm. Res.
          <year>2017</year>
<volume>34</volume>
<fpage>2614</fpage>
<lpage>2627</lpage>
<pub-id pub-id-type="doi">10.1007/s11095-017-2199-y</pub-id>
<pub-id pub-id-type="pmid">28589443</pub-id>
</element-citation>
</ref>
<ref id="B55-jcm-09-01669">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice</article-title>
<source/>Brain Behav. Immun.
          <year>2018</year>
<volume>69</volume>
<fpage>351</fpage>
<lpage>363</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2017.12.009</pub-id>
<pub-id pub-id-type="pmid">29253574</pub-id>
</element-citation>
</ref>
<ref id="B56-jcm-09-01669">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fabbri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Simone</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Canese</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ricceri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Malchiodi-Albedi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fiorentini</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of Rett syndrome</article-title>
<source/>Neuropsychopharmacology
          <year>2012</year>
<volume>37</volume>
<fpage>1152</fpage>
<lpage>1163</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2011.301</pub-id>
<pub-id pub-id-type="pmid">22157810</pub-id>
</element-citation>
</ref>
<ref id="B57-jcm-09-01669">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suwa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Egashira</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kumagai</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo</article-title>
<source/>J. Appl. Physiol. (1985)
          <year>2006</year>
<volume>101</volume>
<fpage>1685</fpage>
<lpage>1692</lpage>
<pub-id pub-id-type="doi">10.1152/japplphysiol.00255.2006</pub-id>
<pub-id pub-id-type="pmid">16902066</pub-id>
</element-citation>
</ref>
<ref id="B58-jcm-09-01669">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Mir</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Nogueira</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fontaine</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Avéret</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rigoulet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leverve</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I</article-title>
<source/>J. Biol. Chem.
          <year>2000</year>
<volume>275</volume>
<fpage>223</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.275.1.223</pub-id>
<pub-id pub-id-type="pmid">10617608</pub-id>
</element-citation>
</ref>
<ref id="B59-jcm-09-01669">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Belmonte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Meloni</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gardi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sticozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cortelazzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alteration of serum lipid profile, SRB1 loss, and impaired Nrf2 activation in CDKL5 disorder</article-title>
<source/>Free Radic. Biol. Med.
          <year>2015</year>
<volume>86</volume>
<fpage>156</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.05.010</pub-id>
<pub-id pub-id-type="pmid">26006105</pub-id>
</element-citation>
</ref>
<ref id="B60-jcm-09-01669">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rius-Pérez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Torres-Cuevas</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Millán</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ortega</surname>
<given-names>Á.L.</given-names>
</name>
<name>
<surname>Pérez</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>PGC-1alpha, Inflammation, and oxidative stress: An integrative view in metabolism</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2020</year>
<volume>2020</volume>
<fpage>1452696</fpage>
<pub-id pub-id-type="doi">10.1155/2020/1452696</pub-id>
<pub-id pub-id-type="pmid">32215168</pub-id>
</element-citation>
</ref>
<ref id="B61-jcm-09-01669">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khacho</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Slack</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dynamics in the regulation of neurogenesis: From development to the adult brain</article-title>
<source/>Dev. Dyn.
          <year>2018</year>
<volume>247</volume>
<fpage>47</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1002/dvdy.24538</pub-id>
<pub-id pub-id-type="pmid">28643345</pub-id>
</element-citation>
</ref>
<ref id="B62-jcm-09-01669">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Son</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Roles of mitochondria in neuronal development</article-title>
<source/>BMB Rep.
          <year>2018</year>
<volume>51</volume>
<fpage>549</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="doi">10.5483/BMBRep.2018.51.11.226</pub-id>
<pub-id pub-id-type="pmid">30269744</pub-id>
</element-citation>
</ref>
<ref id="B63-jcm-09-01669">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Arslanian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Peterokova</surname>
<given-names>V.A.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Tomlinson</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Effect of metformin in pediatric patients with type 2 diabetes: A randomized controlled trial</article-title>
<source/>Diabetes Care
          <year>2002</year>
<volume>25</volume>
<fpage>89</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.2337/diacare.25.1.89</pub-id>
<pub-id pub-id-type="pmid">11772907</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="jcm-09-01669-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Metformin systemic treatment rescues defective energy status in RTT mouse brain. A 10-day long treatment with metformin (100 mg/kg) completely normalizes the reduced mitochondrial ATP production via oxidative phosphorylation (<bold>a</bold>) and ATP levels (<bold>b</bold>) in RTT mouse brain. N = 3. Data are mean ± SEM. Statistical significance was calculated by two-way ANOVA, with Tukey’s <italic>post hoc</italic> test. ** <italic>p</italic> &lt; 0.01. WT: wild-type mice; RTT: MeCP2-308 heterozygous female mice; sal: saline; met: metformin.</p>
</caption>
<graphic xlink:href="jcm-09-01669-g001"></graphic>
</fig>
<fig id="jcm-09-01669-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Metformin treatment restores mitochondrial complex II and V activity in the brain of RTT mice. The activity of complex I (<bold>a</bold>) did not differ between the two genotypes and was not affected by the metformin treatment. The activity of mitochondrial respiratory chain complex II (<bold>b</bold>) and complex V (<bold>c</bold>) was reduced in RTT mouse brain compared to WT controls and metformin treatment restored WT-like levels. N = 3. Data are mean ± SEM. Statistical significance was calculated by two-way ANOVA, with Tukey’s <italic>post hoc</italic> test. * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01. WT: wild-type mice; RTT: MeCP2-308 heterozygous female mice; sal: saline; met: metformin.</p>
</caption>
<graphic xlink:href="jcm-09-01669-g002"></graphic>
</fig>
<fig id="jcm-09-01669-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Metformin treatment normalizes decreased oxidative phosphorylation protein content in RTT mouse hippocampus. Protein expression levels of SDHB (subunit of Complex II) (<bold>c</bold>) and UQCRC2 (subunit of Complex III) (<bold>d</bold>) is decreased in the hippocampus of RTT mice. A trend towards a decrease was also observed for ATP5A (subunit of Complex V) (<bold>f</bold>) in RTT compared to WT controls. No genotype differences were found for NDUFB8 (subunit of Complex I) (<bold>b</bold>) and MTCO1 (subunit of Complex IV) (<bold>e</bold>). Metformin treatment normalized protein expression levels of SDHB (subunit of Complex II) (<bold>c</bold>) and ATP5A (subunit of Complex V) (<bold>f</bold>) in RTT mice. Representative blot is shown in (<bold>a</bold>). N = 9–11. Data are mean ± SEM normalized for WT, sal. Statistical significance was calculated by two-way ANOVA, with Tukey’s <italic>post hoc</italic> test. * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01. WT: wild-type mice; RTT: MeCP2-308 heterozygous female mice; sal: saline; met: metformin; NDUFB8: NADH:Ubiquinone Oxidoreductase Subunit B8; SDHB: Succinate Dehydrogenase Complex Iron Sulfur Subunit B; UQCRC2: Ubiquinol-Cytochrome C Reductase Core Protein II; MTCO1: mitochondrially encoded cytochrome c oxidase I; ATP5A: ATP Synthase, H<sup>+</sup> Transporting, Mitochondrial F1 Complex.</p>
</caption>
<graphic xlink:href="jcm-09-01669-g003"></graphic>
</fig>
<fig id="jcm-09-01669-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Metformin treatment rescues increased oxidative stress status in the brain and in the blood of RTT mice. (<bold>a</bold>) Blood ROS levels, measured as the intensity of formation of CP<sup>•</sup> by EPR, were significantly higher in RTT, sal mice compared to WT controls, confirming the occurrence of a pro-oxidant status in RTT mice. Metformin normalized this value in whole blood of RTT mice to the same level of WT controls. N = 3–4. One subject of the experimental group RTT, sal was identified as outlier and thus, excluded from the analysis. (<bold>b–c</bold>) Metformin treatment reduces the abnormal accumulation of protein 4-hydroxynonenal (HNE) adducts in RTT mouse hippocampus (<bold>c</bold>). Representative blot is shown in panel (<bold>b</bold>). N = 9–11. Data are mean ± SEM normalized for WT, sal. Statistical significance was calculated by two-way ANOVA, with Tukey’s <italic>post hoc</italic> test. * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01. WT: wild-type mice; RTT: MeCP2-308 heterozygous female mice; sal: saline; met: metformin; HNE-adducts: 4-hydroxy-2-trans-nonenal protein bound.</p>
</caption>
<graphic xlink:href="jcm-09-01669-g004"></graphic>
</fig>
<fig id="jcm-09-01669-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>Metformin systemic treatment boosts pathways related to mitochondrial biogenesis and remodeling in RTT mouse brain. PGC-1α protein expression and the levels of its downstream target mtTFA are increased in RTT mouse hippocampus compared to WT controls (<bold>b</bold>). Metformin treatment exacerbates this genotype difference. Following metformin treatment, RTT mouse hippocampus shows an increase in mitochondrial biogenesis related protein OPA1 (<bold>c</bold>) and MFN2 (<bold>d</bold>). Representative blots are reported in (<bold>a</bold>). N = 9–11. Data are mean ± SEM normalized for WT, sal. Statistical significance was calculated by two-way ANOVA, with Tukey’s <italic>post hoc</italic> test. * <italic>p</italic> &lt; 0.05; *** <italic>p</italic> &lt; 0.001. WT: wild-type mice; RTT: MeCP2-308 heterozygous female mice; sal: saline; met: metformin; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; mtTFA: Mitochondrial transcription factor A; OPA1: GTPase Optic Atrophy 1; MFN2: GTPases Mitofusin 2.</p>
</caption>
<graphic xlink:href="jcm-09-01669-g005"></graphic>
</fig>
<fig id="jcm-09-01669-f006" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<p>Metformin systemic treatment boosts pathways related to antioxidant response in RTT mouse brain. Metformin treatment induces an antioxidant response selectively in the hippocampus of RTT mice through the increase of Nrf2 protein expression and activation (<bold>b</bold>), and the corresponding increase in Nrf2 downstream target protein HO-1 (<bold>c</bold>). N = 9–11. Representative blot is included in (<bold>a</bold>). Data are mean ± SEM normalized for WT, sal. Statistical significance was calculated by two-way ANOVA, with Tukey’s <italic>post hoc</italic> test. * <italic>p</italic> &lt; 0.05; ** <italic>p</italic> &lt; 0.01. WT: wild-type mice; RTT: MeCP2-308 heterozygous female mice; sal: saline; met: metformin; Nrf2: nuclear respiratory factor 2; HO-1: heme oxygenase-1.</p>
</caption>
<graphic xlink:href="jcm-09-01669-g006"></graphic>
</fig>
<fig id="jcm-09-01669-f007" orientation="portrait" position="float">
<label>Figure 7</label>
<caption>
<p>A 10-day long treatment with metformin does not affect the compromised general health (GH) status and motor dysfunction of RTT mice. RTT female mice received higher scores compared to WT mice in the GH evaluation (<bold>a</bold>), confirming the presence of phenotypic alterations. No treatment effects were found on this parameter. Total distance moved in the open field test (<bold>b</bold>) does not significantly differ among groups. RTT mice displayed shorter latencies to fall compared to WT controls in the dowel test (<bold>c</bold>). The metformin treatment did not affect the motor performance of the experimental subjects. N = 7–8. Data are mean ± SEM. Statistical significance was calculated by two-way ANOVA. WT: wild-type mice; RTT: MeCP2-308 heterozygous female mice; sal: saline; met: metformin; GH: general health.</p>
</caption>
<graphic xlink:href="jcm-09-01669-g007"></graphic>
</fig>
<fig id="jcm-09-01669-f008" orientation="portrait" position="float">
<label>Figure 8</label>
<caption>
<p>Summary Diagram. A 10-day long treatment with metformin normalizes the reduced mitochondrial ATP production and ATP levels in whole brain of a validated RTT mouse model at an advanced stage of the disease. This is achieved through the restoration of the defective activity of mitochondrial respiratory chain complex II and V and of their reduced protein content. These beneficial effects are accompanied by a strong activation of signaling pathways related to both mitochondrial biogenesis and remodeling (PGC-1α/mtTFA, OPA1 and MFN2) selectively in RTT mouse brain. Metformin also ameliorates prooxidant status and brain oxidative damage in RTT brain, through the stimulation of Nrf2 signaling and the consequent transcription of antioxidant genes such as HO-1. WT: wild-type mice; RTT: MeCP2-308 heterozygous female mice; HNE-adducts: 4-hydroxy-2-trans-nonenal protein bound; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; mtTFA: Mitochondrial transcription factor A; OPA1: GTPase Optic Atrophy 1; MFN2: GTPases Mitofusin 2; ROS: reactive oxidizing species.</p>
</caption>
<graphic xlink:href="jcm-09-01669-g008"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>